Immunology centre director highlights Cuba's development of cancer treatments

December 12, 2002 1:40pm

12/12/2002

agency AIN web site

Havana, 11 December: Cuba is in a vanguard position for cancer research and the proof is immunotherapy, Doctor Agustin Lage, director of the of Molecular Immunology Centre (CIM) in the capital, told AIN [this agency].

He highlighted the development of this procedure for the treatment of malignant tumours with manipulation of the immune system, which is used in the world for the recovery of patients after the fall of leukocytes from chemotherapy.

He also mentioned that interferons are another form of immunotherapy for certain types of cancer, as in renal tumours and melanoma (in the skin), which are already registered.

Immunotherapy will have an increasing role in the treatment of cancer in the current century, meaning in curing patients or in most cases in an extension of survival with a good quality of life, a fundamental objective for this type of illness.

Treatments to the immune system are part of the patient's complex therapy - which includes surgery, radiotherapy, [and] cytostatic [agents] - and they play a role in the therapeutic arsenal for malignant tumours, the expert added.

Dr Lage mentioned that at the moment monoclonal antibodies (AcM) are in clinical tests, with one of these registered in Cuba this year. These are used [for treating] head and neck tumours, while research continues on these products and their use is explored in others.

He also made a reference to cancer vaccines, eight of which are being researched in the country, four of them are undergoing clinical trials.

He pointed out that one of the preventive vaccines or prophylaxes in Cuba is the hepatitis vaccine, because most hepatomas or liver cancers occur after that illness. He said that at this moment there is a decline in hepatitis which will lead to a decrease in the number of liver tumours.

There are about 40 cancer vaccines under research in the world, mainly in highly developed countries such as the United States and Europe.

The Molecular Immunology Centre currently has a monoclonal antibody to treat organ transplant rejections, as well as recombinant erythropoietin [Spanish: "eritropolletina recombinante"], which is used for end-stage renal disease.

Source: AIN news agency, Havana, in Spanish 11 Dec 02